Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Inhibitor

EN460 is a selective endoplasmic reticulum oxidation 1 (ERO1) inhibitor. EN460 (IC₅₀ of 1.9 μM) interacts selectively with the reduced, active form of ERO1α and prevents its reoxidation.

Tafamidis is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC₅₀s of 2.7-3.2 μM. Tafamidis inhibits amyloidogenesis.

QM295 is an endoplasmic reticulum oxidation 1 (ERO1) inhibitor with selectively reversible thiol reactivity. QM295 can be used for the research of endoplasmic reticulum stress.

M6766 is a selective endoplasmic reticulum oxidoreductase 1α (ERO1α) inhibitor with an IC₅₀ of 1.4 μM and a K_D of 1.1 μM. M6766 also inhibits ERO1β with an IC₅₀ of 7.2 μM. M6766 binds to the flavin adenine dinucleotide-binding pocket in ERO1α. M6766 inhibits granule secretion, αIIbβ3 integrin activation, Ca²⁺ mobilization, and platelet aggregation. M6766 can be used for the research of neurological disease, such as ischemic stroke.

Tafamidis (Standard) is the analytical standard of Tafamidis. This product is intended for research and analytical applications. Tafamidis is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis inhibits amyloidogenesis.